IndustryCompany release

Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative

🇺🇸 Microbot Medical Inc. (MBOT) · Mon 16 Nov 2026

The LIBERTY endovascular robot maker blames re-order timing, summer seasonality and hospital reviews, and reports about $62 million in cash and a new Israeli distribution deal.

Microbot Medical Inc. has filed its 10-Q for the quarter ended 30 September 2026, announced on 16 November. Revenue from its LIBERTY endovascular robotic system fell to $72,000, down from $241,000 in the second quarter.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Microbot Medical Inc. ↗

Article written by VigiEye from the official source (Microbot Medical Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →